Ghia P, Pluta A, Wach M, et al. ASCEND phase 3 study of acalabrutinib vs investigator’s choice of rituximab plus idelalisib (IdR) or bendamustine (BR) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). 24th Congress of EHA, abstract LB2606.
Real-life data axicabtagene ciloleucel voor gerecidiveerd of refractair grootcellig B-cellymfoom
jul 2020 | Lymfoom